Lv3
350 积分 2026-04-03 加入
Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up
1个月前
已关闭
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
1个月前
已完结
Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma
1个月前
已完结
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
1个月前
已完结
MON-446 Immunotherapy Induced Thyroiditis Secondary to Nivolumab
2个月前
已完结
Immune checkpoint inhibitor-induced thyroiditis and its potential mechanisms
2个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
4个月前
已完结
Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC
4个月前
已完结
Molecular Profiling across 80,000 Patients with Lung Cancer
4个月前
已完结
Immune checkpoint inhibitors in melanoma
4个月前
已完结
皖公网安备34019202002308
